Protagonist Therapeutics Email Addresses

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target the same biological pathways for which there are marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer preferential drug exposure in the gastrointestinal (GI) tissue compartment, the potential for improved safety due to minimal exposure in the blood, improved convenience and compliance, and potentially an opportunity for the earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's oral peptide product candidates, PTG-100 and PTG-200, are based on this approach with the potential to transform the existing treatment paradigm for IBD, which includes both ulcerative colitis and Crohn's disease. PTG-100, a potential first-in-class oral alpha4beta7 integrin antagonist, is being developed initially for moderate-to-severe active ulcerative colitis. PTG-200, a potential first-in-class oral IL-23 receptor antagonist, is being developed initially for Crohn's disease and is currently in IND-enabling studies. The company has a peptide technology platform that enables the discovery of oral and injectable peptides that can be utilized against a diverse set of targets and diseases including, but not restricted to GI disease. In addition to PTG-100 and PTG-200, the company is also engaged in the discovery and development of an injectable hepcidin mimetic, PTG-300, which is currently in IND-enabling studies. PTG-300 has potential utility for the treatment of iron overload disorders such as beta-thalassemia, which may qualify PTG-300 for orphan drug designation. Protagonist is headquartered in Milpitas, California with its pre-clinical and clinical development staff in California, and discovery operations in both California and Brisbane, Queensland, Australia.